Riboxin 200 mg tablets # 50

Riboxin (RIBOXIN) instructions for use

Composition

active ingredient: inosine; 1 tablet contains inosine (in terms of 100% dry matter) - 200 mg;
auxiliary substances: microcrystalline cellulose, magnesium stearate.
film coating: hydroxypropylmethylcellulose, copolyvidone, polyethylene glycol, medium chain triglycerides, polydextrose, titanium dioxide (E171), iron oxide red (E172), iron oxide yellow (E172)

Dosage form

Film-coated tablets.

Pharmacological group

Cardiological preparations . Inosine. ATS C01E C code

Indications

• In the complex therapy of coronary heart disease (after a myocardial infarction, angina pectoris), heart rhythm disturbances, intoxication with cardiac glycoside preparations, treatment of cardiomyopathies of various genesis, myocardiodystrophies (caused by physical stresses, infectious and endocrine origin), myocarditis;
• urocoppororphyria; liver disease (hepatitis, liver cirrhosis, fatty liver disease).

Contraindications

• Hypersensitivity to inosine or other components of the drug
• hyperuricemia;
• renal insufficiency
• gout.

Dosing and Administration

Tablets should be taken orally, before eating, without chewing, with plenty of liquid. The daily dose is determined individually and is for adults 600-2400 mg (3-12 tablets).

Adults in the first days of treatment daily dose is 600-800 mg (1 tablet 3-4 times a day). If the drug is well tolerated, increase the dose for 2-3 days from 1200 mg (2 tablets 3 times daily) to 2,400 mg.

The duration of the course of treatment is from 4 weeks to 1.5-3 months.

When urokoprofirii daily dose is 800 mg (1 tablet 4 times a day), the duration of treatment - 1-3 months.

Adverse Reactions

From the immune system, skin and subcutaneous tissue: allergic / anaphylactic reactions (including itching, skin hyperemia, urticaria, rash, anaphylactic shock).

On the part of metabolism, metabolism: hyperuricemia, with prolonged use in large doses may exacerbate gout.

Cardiac disorders: tachycardia, arterial hypotension, may be accompanied by a headache, shortness of breath, dizziness, nausea, vomiting, sweating.

Other: increased levels of uric acid in the blood, a general weakness.

Overdose

Symptoms: increased side effects, allergic reactions, nausea, diarrhea, abdominal pain.

Treatment: withdrawal of the drug and symptomatic therapy.

Use during pregnancy and lactation

The study of the efficacy and safety of the use of the drug in this group of patients was not conducted, so it should not be used during pregnancy and lactation.

Children

Do not use for children because of lack of safety data.

Application features

Inosine is not used for urgent correction of cardiac dysfunction.

When itching and hyperemia of the skin, treatment with the drug should be discarded.

Riboxin tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome should not take the drug.

In case of kidney disease, it is advisable to prescribe the drug only when, in the doctor's opinion, the expected effect exceeds the possible risk of application.

With prolonged use of inosine should monitor the concentration of uric acid in the blood and urine.

The ability to influence the reaction rate when driving vehicles or other mechanisms

The drug does not affect the ability to drive vehicles or work with other mechanisms.

Interaction with other drugs and other interactions

When used with cardiac glycosides, inosine prevents the development of arrhythmias, enhances the positive inotropic effect.

Inosine can be used simultaneously with anabolic drugs (potassium orotate, methandrostenolone), nitroglycerin, nifedipine, furosemide, spironolactone.

With the simultaneous use of inosine with beta-adrenoblockers, the effectiveness of inosine does not decrease.

Riboxin increases the duration of action of heparin.

With tannin forms a precipitate.

With hypouricemic drugs, it weakens the effects of hypouricemic agents.

Pharmacological properties

Pharmacodynamics.

Inosine refers to anabolic substances, is purine nucleoside, a precursor to the synthesis of ATP. It exhibits antihypoxic and antiarrhythmic properties, has anabolic effect.

Inosine positively affects the metabolism in the myocardium, increases the energy balance of cells, stimulates the synthesis of nucleotides, increases the activity of certain enzymes of the Krebs cycle. The drug increases the strength of the heartbeats and promotes more complete relaxation of the myocardium in diastole due to the ability to bind calcium ions, which penetrated into the cells during their excitation. As a result, the shock volume of the heart increases, the blood supply of the myocardium improves, including coronary circulation.

Inosin accelerates the dissociation of oxygen from oxyhemoglobin, which improves the enrichment of tissues with oxygen and improves coronary circulation. The drug normalizes the function of the liver by improving energy processes in hepatocytes, participates in the exchange of glucose and promotes the activation of glucose metabolism in hypoxia.Inosin intensifies the metabolism of pyruvic acid, promotes an increase in the activity of xanthine dehydrogenase. The drug also reduces platelet aggregation, activates the regeneration of tissues (especially the myocardium and the mucous membrane of the gastrointestinal tract).

Pharmacokinetics .

When ingestion is well absorbed in the gastrointestinal tract. Metabolised in the liver with the formation of glucuronic acid and its subsequent oxidation. In an insignificant amount is excreted in the urine.

Basic physical and chemical properties

tablets of round shape, with biconvex surface, covered with a film membrane from yellow to brownish-yellow color.

Shelf life

3 years.

Storage conditions

In the original packaging at a temperature of no higher than 25 ° C. Keep out of the reach of children.

Packaging

For 10 tablets in a blister, 5 blisters per pack.

Category of leave

On prescription.